


# Perinatal Mood and Anxiety Disorders, Beyond SSRI's

September 16, 2025



**Sarah Guth, MD, Perinatal Psychiatrist, UVMHC  
Medical Director VTCPAP Perinatal Service**

# Presentation Outline

- Common Scenarios
- How to choose a second line medication
- Risks associated with second line medications
- Medications in Breastfeeding



# Common scenario 1:

## Depression in Pregnancy, patient says SSRI's don't work for them

You have identified Predominantly Low Mood for two weeks or more, or Lack of ability to find pleasure over a similar timeframe.

EPDS= 10 or higher

PHQ9= 10 or higher

Rule out hyperemesis or anemia as root cause



# Common scenario 1:

## Depression in Pregnancy, person says SSRI's don't work for them



Have they had any truly adequate trials?  
Were they in adolescence?  
Adolescents are more likely to experience agitation.  
Try again, low and slow.  
Escitalopram 5 mg is well tolerated

# Common scenario 1:

## Depression in Pregnancy, person says SSRI's don't work for them



Have they had two fair trials that weren't helpful? Try an SNRI. (Same safety profile). Failed SNRI also?

May be heading to second line

# Common scenario 1:

**Depression in Pregnancy, person says SSRI's don't work for them**

**Consider, are they sleeping?** Is there room to address sleep?



**Are they in therapy?** Is there room for support through therapy or support groups?



# Common Scenario 2

**Depression in Pregnancy, person is already maxed out on SSRI.**

**Consider increasing above maximum dose.**

Metabolism changes in pregnancy can decrease the level. CYP2C19 activity decreases CYP2D6 increases

May need EKG (escitalopram)

**Are there any medications they have taken in the past that they stopped for pregnancy?**

Stopping *stimulants* is associated with increase in depression; Stopping *mood stabilizers* can precipitate depression



# What can we add or use instead?

You've addressed sleep. You've maxed SSRI

There are no other medications to restart, therapist referral in place. What next?





# Bupropion in Pregnancy

- **Birth Defects:** Most large studies show **no increase**
- **Cardiac Malformations** (specifically): some small studies show **small increase** (*confounded by cigarette smoking*) ; 2.1-2.8 per 1,000 births.
- **Miscarriage rate:** **within population norm.**
- Neonatal Adaptation Syndrome: less than w/SSRI but **increased**
- **Neurodevelopment:** **Small increase** in ADHD in offspring related to bupropion exposure in second trimester. Small study, needs replication

# Bupropion in pregnancy

Works for some,  
not everyone.

Can improve energy  
and motivation, but  
can worsen anxiety and  
sleep.



# Mirtazapine

**Improves sleep and appetite. Also helps with hyperemesis**

**Miscarriage:** risk slightly **increased**

**Congenital Malformations:** **No increased risk**

**Pre-eclampsia and Postpartum Hemorrhage:** **No increased risk**

**Preterm Labor and Low Birthweight:** **No increased risk**

**Neonatal Adaptation Symptoms:** **~30-50%**

**Neonatal NICU stays:** **No increase**

**Neurodevelopment:** **No increased risk of Autism**

# Antipsychotics

In case of moderate to severe depression, especially with suicidal ideation, or aggression, mood stabilizers can help.

Low dose antipsychotic is preferred:

5 mg of Abilify - when sedation is unwanted

1 mg of Risperidone (can be dosed BID)- can cause mild sedation and can be used as a PRN in case of agitated depression

# Antipsychotics

Miscarriages- **no increased** risk

Congenital malformations- **equivocal**, slightly increased according to one study, no increase in large US, Nordic and Japanese cohorts

Preterm birth: **Small Increased** risk

Low birthweight: **No increased** risk

Neonatal Complications: **Small increased risk** about same as with SSRIs ~30%

Neurodevelopment: **no increased risk** of neurodev conditions

# Common Scenario 3

Patient presents with Anxiety in Pregnancy (and they are maxed out on SSRI or unable to take them).

EPDS #4, 5 and 6, Maximally Endorsed  
Or GAD-7 10 or higher

**Edinburgh Postnatal Depression Scale<sup>1</sup> (EPDS)**

Your full name: \_\_\_\_\_ Date: \_\_\_\_\_  
Your baby's date of birth: \_\_\_\_\_ Your address: \_\_\_\_\_  
Your phone number: \_\_\_\_\_

Postnatal depression is the most common complication during pregnancy and after giving birth. And since you're currently pregnant or have given birth recently, we want to know how you've been feeling. Here is a 10-item questionnaire for you to answer so we can gauge how you're feeling. For each item, tick the checkbox that comes closest to how you've been feeling for the past 7 days, not just today.

Please note that the total score will be calculated by the person who administered this test.

In the past 7 days:


<b>1. I have been able to laugh and see the funny side of things</b> <input type="checkbox"/> As much as I always could <input type="checkbox"/> Not quite so much now <input type="checkbox"/> Definitely not so much now <input type="checkbox"/> Not at all	<b>*6. Things have been getting on top of me</b> <input type="checkbox"/> Yes, most of the time I haven't been able to cope at all <input type="checkbox"/> Yes, sometimes I haven't been coping as well as usual <input type="checkbox"/> No, most of the time I have coped quite well <input type="checkbox"/> No, I have been coping as well as ever
<b>2. I have looked forward with enjoyment to things</b> <input type="checkbox"/> As much as I ever did <input type="checkbox"/> Rather less than I used to <input type="checkbox"/> Definitely less than I used to <input type="checkbox"/> Hardly at all	<b>*7. I have lost so much interest in things that I have had difficulty doing</b> <input type="checkbox"/> Yes, most of the time <input type="checkbox"/> Yes, sometimes <input type="checkbox"/> Not very often <input type="checkbox"/> No, not at all
<b>*3. I have blamed myself unnecessarily when things went wrong</b> <input type="checkbox"/> Yes, most of the time <input type="checkbox"/> Yes, some of the time <input type="checkbox"/> Not very often <input type="checkbox"/> No, never	<b>*8. I have felt sad or miserable</b> <input type="checkbox"/> Yes, most of the time <input type="checkbox"/> Yes, quite often <input type="checkbox"/> Yes, quite often <input type="checkbox"/> Not very often <input type="checkbox"/> No, not at all
<b>4. I have been anxious or worried for no good reason</b> <input type="checkbox"/> No, not at all <input type="checkbox"/> Hardly ever <input type="checkbox"/> Yes, sometimes <input type="checkbox"/> Yes, very often	<b>*9. I have been so unhappy that I have been crying</b> <input type="checkbox"/> Yes, most of the time <input type="checkbox"/> Yes, quite often <input type="checkbox"/> Yes, quite often <input type="checkbox"/> Only occasionally <input type="checkbox"/> No, never
<b>*5. I have felt scared or panicky for no very good reason</b> <input type="checkbox"/> Yes, quite a lot <input type="checkbox"/> Yes, sometimes <input type="checkbox"/> No, not much <input type="checkbox"/> No, not at all	<b>*10. The thought of harming myself has occurred to me</b> <input type="checkbox"/> Yes, quite a lot <input type="checkbox"/> Sometimes <input type="checkbox"/> Hardly ever <input type="checkbox"/> Never

Administered/reviewed by: \_\_\_\_\_ Total Score: \_\_\_\_\_  
Date: \_\_\_\_\_

<sup>1</sup>Source: Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. *British Journal of Psychiatry* 150:782-786.

<sup>2</sup>Source: K. L. Wisner, B. L. Parry, C. M. Ploncke, Postpartum Depression N Engl J Med vol. 347, No 3, July 18, 2002, 194-199

Users may reproduce the scale without further permission providing they respect copyright by quoting the names of the authors, the title and the source of the paper in all reproduced copies.

<https://carepatron.com> 

# Common Scenario 3

You have maximized SSRI, you have made the therapy referral, you have addressed sleep. What are your second lines?

Buspar

Propranolol

Benzodiazepines: Lorazepam

Hydroxyzine

2




# Daily Medication: Buspirone

Buspar- A *daily* medication, known for being effective in a small percentage of people

Prospective study- 72 women taking it in first tri and **no major malformations**

Protects against stress and pain transmission in female rats in pregnancy, also protective against the effects of maternal alcohol use



# PRN or Daily: Propranolol

Propranolol- used for HTN, Thyroid, migraines

Old data: associated with SGA, hypoglycemia and bradycardia at birth; though not preterm labor



# PRN Medication: Benzodiazepines

Research is back and forth, but recent 2024 meta-analysis showed:

Miscarriage: when exposed to at least one prescription in first tri **OR: 1.69, NNH 15**

Congenital and Cardiac Malformations: Slight **increased** risk\*

Preterm Labor, Low Birth weight: Slight **increased** risk, limited to third tri\*

Low APGAR: Slight **increased** risk\*

Neurodevelopment: **No increased** risk of Autism, ADHD or other effects

\*Small but increased OR's (from 1.13 to 1.45) NNH between 200 and 300

# PRNs: Hydroxyzine

Hydroxyzine- Prospective study, 120 women, **no increased risk of birth defects** but no other outcomes studied :(

Neonatal seizures 150 and 600 mg case studies



# Antipsychotics

Like depression, when anxiety is severe, this class is helpful

5 mg of Abilify - when sedation is unwanted

1 mg of Risperidone (can be dosed BID)- can cause mild sedation and can be used as a PRN in case of agitated depression

# Postpartum Considerations

## Different Considerations....

1. Sedation: medication with sedation can prevent safe baby care. People's responses vary widely to different medications so always good to have them start medications when they have help available to see how alert they are.
2. Relative infant dose

$$RID = \frac{\text{Dose.infant} \left( \frac{\text{mg/kg}}{\text{day}} \right)}{\text{Dose.mother} \left( \frac{\text{mg/kg}}{\text{day}} \right)}$$

Dose.infant = dose in infant/day  
Dose.mother = dose in mother/day

**Lactmed**

**<https://www.ncbi.nlm.nih.gov/books/NBK501922/>**

# Postpartum Considerations

Drug	RID (%)	Side Effects / Notes
Bupropion	2–5	Seizures, jitteriness, GI effects; + SSRIs
Mirtazapine	0.6–2.8	No observed sedation
Aripiprazole	0.7–12.7	May inhibit production; no infant effects
Risperidone	0–4.7	Generally tolerated; 1 preterm resp. distress
Buspirone	~1	No production effects; no infant effects
Propranolol	<1	Possibly infant sleepiness
Lorazepam	Up to 8	No sedation observed in infants
Hydroxyzine	N/A	Case reports of infant drowsiness



# New Kid on the Block

## Zuranolone- allopregnanolone

Different mechanism of action.

Works very quickly (relief on day 3).

Individuals take it 14 nights in a row and then stop and the effect continues afterwards.

Not trialed in breastfeeding, but low RID

**NEW MEDICATION  
FOR  
POSTPARTUM  
DEPRESSION**

# Zuranolone

Who is eligible?-

- Strict requirement, depression began no earlier than third trimester, no later than one month postpartum (though they can start it later than that, the symptoms had to have begun)
- Depression must be **severe**
- Okay to be on other medications, okay to have psychosis but won't help psychosis
- Because of sedation, must have help with baby at night, no driving 12h after taking

# VTCPAP 802-488-5342


## Perinatal Psychiatric Consultation



**Sarah E. Guth, MD**  
*Psychiatrist &  
Perinatal Program  
Medical Director*



**Eliza Pillard, LICSW**  
*(she/her)  
Pediatric & Perinatal  
Liaison Coordinator*



**support  
DELIVERED**

**Services include:**

- » EVIDENCE-BASED GUIDANCE AROUND PRESCRIBING PSYCHOTROPIC MEDICATIONS TO THE PERINATAL POPULATION
- » GUIDANCE ON SCREENING, ASSESSMENT, DIAGNOSIS, AND RECOMMENDED TREATMENT STRATEGIES

**Perinatal Psychiatric Consultation Service**

- » **As many as 1 in 4 women** suffer from symptoms of depression and/or anxiety during the perinatal period
- » **Perinatal Mood and Anxiety Disorders (PMADs)** are the most common complication associated with childbearing
- » **Prescribing clinicians may be the first**, and possibly the only, providers to work with Vermonters and families struggling with PMADs
- » **Professional consultation** and resources regarding PMADs are available for obstetrics & gynecology, primary care, pediatric, psychiatric, and other community providers


**Free consultations are available for medical providers Call (802) 488-5342**

This is a free service provided in collaboration with the Vermont Department of Health


You may call anytime and you will typically receive a reply by phone or email, depending on your preference, from a psychiatric provider within one business day.

Consults may be single questions or may involve ongoing contact for complex issues. At times the consultations may involve face to face evaluations of the patient by the psychiatric provider with a written evaluation.

**For additional information on PMADs and Vermont-specific resources visit [SupportDeliveredVT.com](http://SupportDeliveredVT.com)**



The Vermont Department of Health and the Vermont Department of Mental Health are collaborating on the Screening, Treatment, & Services for Maternal & Perinatal Program (STAMP), a 5-year collaborative agreement funded by SAMHSA to help support perinatal mental health services in Vermont.



# Resource & Referral

Our Team Of Liaison Coordinators can assist with:

- **Psychoeducational materials** and resources
- **Referral information** to therapists and other mental health services
- Information on **community-based resources**



# References

Poweleit EA, Cinibulk MA, Novotny SA, Wagner-Schuman M, Ramsey LB, Strawn JR. Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications. *Front Pharmacol*. 2022 Feb 25;13:833217. doi: 10.3389/fphar.2022.833217. PMID: 35281909; PMCID: PMC8916222.

Hendrick V, Suri R, Gitlin MJ, Ortiz-Portillo E. Bupropion Use During Pregnancy: A Systematic Review. *Prim Care Companion CNS Disord*. 2017

Ornoy A, Koren G. The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review. *Curr Neuropharmacol*. 2021;19(11):1794-1804.

Ostenfeld A, Lyngholm S, Christensen SE, Petersen TS, Andersen JT, Westergaard HB, Pedersen LH, Løkkegaard ECL. Mirtazapine in pregnancy and lactation: A systematic review of adverse outcomes. *Acta Psychiatr Scand*. 2025 Jan;151(1):6-32. doi: 10.1111/acps.13749. Epub 2024 Aug 31. PMID: 39215625; PMCID: PMC11608810.

# References

Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy Outcomes Following In Utero Exposure to Second-Generation Antipsychotics: A Systematic Review and Meta-Analysis. *J Clin Psychopharmacol*. 2015 Oct;35(5):559-65. doi: 10.1097/JCP.0000000000000391. PMID: 26274044.

Yakuwa N, Takahashi K, Anzai T, Ito N, Goto M, Koinuma S, Uno C, Suzuki T, Watanabe O, Yamatani A, Murashima A. Pregnancy Outcomes With Exposure to Second-Generation Antipsychotics During the First Trimester. *J Clin Psychiatry*. 2022 Jun 8;83(4):21m14081. doi: 10.4088/JCP.21m14081. PMID: 35687862.

Viguera AC, McElheny SA, Caplin PS, Kobylski LA, Rossa ET, Young AV, Gaccione P, Góez-Mogollón L, Freeman MP, Cohen LS. Risk of Poor Neonatal Adaptation Syndrome Among Infants Exposed to Second-Generation Atypical Antipsychotics Compared to Antidepressants: Results From the National Pregnancy Registry for Psychiatric Medications. *J Clin Psychiatry*. 2023 Jan 4;84(1):22m14492. doi: 10.4088/JCP.22m14492. PMID: 36602927.

Straub L, Hernández-Díaz S, Bateman BT, Wisner KL, Gray KJ, Pennell PB, Lester B, McDougle CJ, Suarez EA, Zhu Y, Zakoul H, Mogun H, Huybrechts KF. Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders: A National Birth Cohort Study. *JAMA Intern Med*. 2022 May 1;182(5):522-533. doi: 10.1001/jamainternmed.2022.0375. PMID: 35343998; PMCID: PMC8961398.

# References

Freeman MP, Szpunar MJ, Kobylski LA, Harmon H, Viguera AC, Cohen LS. Pregnancy outcomes after first-trimester exposure to buspirone: prospective longitudinal outcomes from the MGH National Pregnancy Registry for Psychiatric Medications. Arch Womens Ment Health. 2022 Oct;25(5):923-928. doi: 10.1007/s00737-022-01250-8. Epub 2022 Jul 16. PMID: 35840767. Wu HN, Liang Y, Li LL, Jiang HY, Xu LL. The safety of benzodiazepines and related drugs during pregnancy: an updated meta-analysis of cohort studies. Arch Gynecol Obstet. 2024 Jul;310(1):45-54.

<https://mothertobaby.org/fact-sheets/propranolol/>

Wu HN, Liang Y, Li LL, Jiang HY, Xu LL. The safety of benzodiazepines and related drugs during pregnancy: an updated meta-analysis of cohort studies. Arch Gynecol Obstet. 2024 Jul;310(1):45-54. doi: 10.1007/s00404-024-07557-4. Epub 2024 May 28. PMID: 38806942.

Meng LC, Lin CW, Chuang HM, Chen LK, Hsiao FY. Benzodiazepine Use During Pregnancy and Risk of Miscarriage. JAMA Psychiatry. 2024 Apr 1;81(4):366-373. doi: 10.1001/jamapsychiatry.2023.4912. PMID: 38150230; PMCID: PMC10753441.

Chan AYL, Gao L, Howard LM, Simonoff E, Coghill D, Ip P, Lau WCY, Taxis K, Wong ICK, Man KKC. Maternal Benzodiazepines and Z-Drugs Use during Pregnancy and Adverse Birth and Neurodevelopmental Outcomes in Offspring: A Population-Based Cohort Study. Psychother Psychosom. 2023;92(2):113-123. doi: 10.1159/000529141. Epub 2023 Mar 10. PMID: 36907183.



# References

Chen VC, Chen YL, Kao KL, Lee YC, Lu ML, Wu SI, Stewart R. Risks of prematurity and low birth weight associated with trimester-specific prenatal benzodiazepine exposure. *J Psychiatry Neurosci*. 2025 Aug 26;50(4):E310-E317. doi: 10.1503/jpn.240063. PMID: 40858335.

Einarson A, Bailey B, Jung G, Spizzirri D, Baillie M, Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. *Ann Allergy Asthma Immunol*. 1997 Feb;78(2):183-6. doi: 10.1016/S1081-1206(10)63385-6. PMID: 9048526. Jul;310(1):45-54. doi: 10.1007/s00404-024-07557-4. Epub 2024 May 28. PMID: 38806942.

<https://www.ncbi.nlm.nih.gov/books/NBK501922/>

Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J. Zuranolone for the Treatment of Postpartum Depression. *Am J Psychiatry*. 2023 Sep 1;180(9):668-675. doi: 10.1176/appi.ajp.20220785. Epub 2023 Jul 26. Erratum in: *Am J Psychiatry*. 2025 Mar 1;182(3):311. doi: 10.1176/appi.ajp.20220785correction. PMID: 37491938.

# Survey. Thanks

<https://redcap.link/4akubr75>

